{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T06:59:26Z","timestamp":1763535566716,"version":"build-2065373602"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.ejca.2018.11.018","type":"journal-article","created":{"date-parts":[[2018,12,20]],"date-time":"2018-12-20T17:38:09Z","timestamp":1545327489000},"page":"175-185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system"],"prefix":"10.1016","volume":"107","author":[{"given":"James","family":"Larkin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana M.","family":"Arance","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Hauschild","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Queirolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele Del","family":"Vecchio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo A.","family":"Ascierto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"Krajsov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Schachter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart","family":"Neyns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus","family":"Garbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanna Chiarion","family":"Sileni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Mandal\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Gogas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geke","family":"Hospers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Lorigan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Nyakas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Guminski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Liszkay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Rutkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Wilson","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarita","family":"Donica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Makrutzki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Blank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.ejca.2018.11.018_bib1","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"issue":"9839","key":"10.1016\/j.ejca.2018.11.018_bib2","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ejca.2018.11.018_bib3","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol"},{"issue":"9992","key":"10.1016\/j.ejca.2018.11.018_bib4","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ejca.2018.11.018_bib5","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejca.2018.11.018_bib6","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2018.11.018_bib7","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S1470-2045(14)70051-8","article-title":"Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study","volume":"15","author":"Larkin","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2018.11.018_bib8","first-page":"793","article-title":"Baseline and post baseline characteristics associated with treatment benefit across dabrafenib and trametinib registration pooled data","volume":"28","author":"Long","year":"2015","journal-title":"Pigment Cell Melanoma Res"},{"year":"2016","series-title":"Clinical predictors of survival with cobimetinib (C) combined with vemurafenib (V): pooled analysis from BRIM7 and coBRIM","author":"Ascierto","key":"10.1016\/j.ejca.2018.11.018_bib9"},{"issue":"8","key":"10.1016\/j.ejca.2018.11.018_bib10","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ejca.2018.11.018_bib11","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","article-title":"Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study","volume":"15","author":"McArthur","year":"2014","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2018.11.018_bib12","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/S1470-2045(14)70301-8","article-title":"Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study","volume":"15","author":"Ribas","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2018.11.018_bib13","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ejca.2017.04.007","article-title":"Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis","volume":"79","author":"Blank","year":"2017","journal-title":"Eur J Cancer"},{"issue":"14","key":"10.1016\/j.ejca.2018.11.018_bib14","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1158\/1078-0432.CCR-14-2023","article-title":"PD-L1 expression and tumor-infiltrating lymphocytes define different subsets of MAPK inhibitor-treated melanoma patients","volume":"21","author":"Kakavand","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.ejca.2018.11.018_bib15","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1158\/1078-0432.CCR-11-2479","article-title":"Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma","volume":"18","author":"Wilmott","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.ejca.2018.11.018_bib16","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1158\/1078-0432.CCR-12-1630","article-title":"BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma","volume":"19","author":"Frederick","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2018.11.018_bib17","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.9536","article-title":"Identifying prognostic subgroups for outcomes in BRAFV600-mutated metastatic melanoma patients (pts) treated with vemurafenib (V) \u00b1 cobimetinib (C): a pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM","volume":"34","author":"Larkin","year":"2016","journal-title":"J Clin Oncol"},{"year":"2016","series-title":"Identification of prognostic subgroups for overall survival in patients with BRAFV600-mutated metastatic melanoma treated with vemurafenib \u00b1 cobimetinib: a pooled exploratory analysis of the BRIM-2, BRIM-3, BRIM-7, and coBRIM studies","author":"Hauschild","key":"10.1016\/j.ejca.2018.11.018_bib18"},{"issue":"1","key":"10.1016\/j.ejca.2018.11.018_bib19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918315168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918315168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:22:47Z","timestamp":1760732567000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804918315168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":19,"alternative-id":["S0959804918315168"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.11.018","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.11.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}